TY - JOUR AU - MacIsaac, Richard J. AU - Lee, Melissa H. AU - McAuley, Sybil A. AU - Ward, Glenn M. AU - O’Neal, David N. PY - 2018 TI - Empagliflozin as an adjunctive therapy for type 1 diabetes JF - Annals of Translational Medicine; Vol 6, Supplement 2 (December 29, 2018): Annals of Translational Medicine Y2 - 2018 KW - N2 - Long-term complications of type 1 diabetes (T1D) due to exposure to chronic hyperglycaemia, including blindness, amputations, cardiovascular disease and kidney failure, remain a fear for many people living with T1D. Intensive insulin therapy reduces the risk of complications, but the majority of people with T1D fail to achieve recommended glycaemic targets (1-3). Furthermore, long-term intensive insulin therapy is associated with weight gain, a relevant side-effect as a significant proportion of people with T1D are now overweight (4). UR - https://atm.amegroups.org/article/view/23145